Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Forecast | Non-Small-Cell Lung Carcinoma (NSCLC) Prevalent population

Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Forecast | Non-Small-Cell Lung Carcinoma (NSCLC) Prevalent population

“DelveInsight Business Research LLP”
DelveInsight’s ‘Non-Small-Cell Lung Carcinoma (NSCLC) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas and sarcomatoid carcinomas.

NSCLC can be located in the mid-chest, but it is often also found in other parts of the lung too. Even though NSCLCs are associated with cigarette smoking, adenocarcinomas may also be found in patients who have never smoked. Also, itis relatively insensitive to chemotherapy and radiation therapy in comparison with SCLC.

DelveInsight’s ‘Non-Small Cell Lung Cancer – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Non-Small Cell Lung Cancer Epidemiology

The Non-Small Cell Lung Cancer epidemiology division provides insights about historical and current Non-Small Cell Lung Cancer patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.

Non-Small Cell Lung Cancer Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030 segmented into:

  • Total Incident cases of NSCLC patients,
  • Total Incident cases of NSCLC patients by Histology,
  • Total Diagnosed cases of NSCLC patients by Stages,
  • Total NSCLC cases of patients by Genetic mutation/Biomarkers, and
  • Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC

Click to know more about Non-small cell lung cancer.

The Non-Small Cell Lung Cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Non-Small Cell Lung Cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-Small Cell Lung Cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Request for sample pages: https://www.delveinsight.com/report-store/non-small-cell-lung-carcinoma-nsclc-epidemiology-forecast

Table of Contents

  1. Key Insights
  2. Executive Summary of Non-Small Cell Lung Cancer
  3. Non-Small Cell Lung Cancer: Disease Background and Overview
  4. Patient Journey
  5. Epidemiology and Patient Population
  • Epidemiology Scenario: 7MM
  • United States Epidemiology
  • EU-5 Country-wise Epidemiology
  • Japan Epidemiology
  1. Treatment Algorithm, Current Treatment, and Medical Practices
  2. KOL Views
  3. Unmet Needs
  4. Appendix
  5. DelveInsight Capabilities
  6. Disclaimer

*The table of contents is not exhaustive; will be provided in the final report

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/